Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor

US9376396B2 · kind B2 · utility

Assignees

• Abb Vie Deutschland Gmbh & Co. KG · DE
• Abb Vie Inc. · US

Inventors

• Andreas Haupt · Ludwigshafen, DE
• Jurgen Dinges · Wadsworth, US
• Liliane Unger · Ludwigshafen, DE
• Karsten Wicke · Ludwigshafen, DE
• Robert Van Waterschoot · Riehen, CH
• Scott Mittelstadt · North Chicago, US
• Karla Drescher · Ludwigshafen, DE
• Ana-Lucia Relo · Ludwigshafen, DE

Key dates

• Filing date: Oct 11, 2013
• Grant date: Jun 28, 2016
• Expiry date: Oct 11, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor.